Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

(2016) Tadakatsu Nakamura et al.   Drug Design Development and Therapy

P.3.d.053 Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial

(2015) M. Debelle et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO

(2015) Ragy R. Girgis et al.   SCHIZOPHRENIA RESEARCH

P.3.d.022 Cariprazine in negative symptoms of schizophrenia: post hoc analyses of a fixed-dose, placebo- and active-controlled trial

(2014) M. Debelle et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse

(2012) Ross Zimnisky et al.   PSYCHOPHARMACOLOGY

Brain uptake and distribution of the dopamine D3/D2receptor partial agonist [11C]cariprazine: An in vivo positron emission tomography study in nonhuman primates

(2012) Miklós Tóth et al.   SYNAPSE

The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults

(2011) Kelly Posner et al.   AMERICAN JOURNAL OF PSYCHIATRY

In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors

(2011) Yoshihiro Tadori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

(2011) Laura Redden et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

(2011) Nicholas Seneca et al.   PSYCHOPHARMACOLOGY

Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO

(2011) Romina Mizrahi et al.   SCHIZOPHRENIA RESEARCH

Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo

(2011) Jean-Dominique Gallezot et al.   SYNAPSE

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

(2010) Graham Searle et al.   BIOLOGICAL PSYCHIATRY

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO

(2010) Ragy R Girgis et al.   NEUROPSYCHOPHARMACOLOGY

P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients

(2009) S. Potkin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925

(2009) Ariel Graff-Guerrero et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice

(2009) Eugenii A. Rabiner et al.   SYNAPSE

P.3.c.051 Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers

(2008) M. Kapás et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15

(2008) István Gyertyán et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15

(2008) Béla Kiss et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study

(2008) Ariel Graff-Guerrero et al.   NEUROPSYCHOPHARMACOLOGY